RecruitingPhase 1NCT07616934

A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-A1 in Healthy Young Adults

A Phase 1, First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-A1 in Healthy Young Adults

Sponsor

Vaxcyte, Inc.

Enrollment

80 participants

Start Date

Jun 1, 2026

Study Type

INTERVENTIONAL

Conditions

Group A streptococcal infection

Summary

This is a phase 1, first-in-human, randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the safety, tolerability, and immunogenicity of VAX-A1 in healthy adults 18-40 years of age.

Eligibility

Min Age: 18 YearsMax Age: 40 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called Placebo, a biological treatment called VAX-A1 High, and others for people with group a streptococcal infection. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 40 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALPlacebo

0.5mL of placebo (normal saline) will be administered into the deltoid muscle

BIOLOGICALVAX-A1 Low

0.5mL of the low dose VAX-A1 will be administered into the deltoid muscle

BIOLOGICALVAX-A1 Mid

0.5mL of the mid dose VAX-A1 will be administered into the deltoid muscle

BIOLOGICALVAX-A1 High

0.5mL of the high dose VAX-A1 will be administered into the deltoid muscle

Locations(1)

Fusion Clinical Research

Adelaide, South Australia, Australia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07616934